The Role of High-Frequency Antigenic Variation in The Pathogenesis of Mycoplasma infection. The main goal of the proposed project is to understand the molecular mechanisms of phase/antigenic variation and its effects on mycoplasma pathogenesis. In this context I will use the well-characterised Mycoplasma synoviae haemagglutinin, MSPA, to establish the role of its phase-variable expression in the type and extent of M. synoviae disease. Additionally, the relationship between MSPA phase variation a ....The Role of High-Frequency Antigenic Variation in The Pathogenesis of Mycoplasma infection. The main goal of the proposed project is to understand the molecular mechanisms of phase/antigenic variation and its effects on mycoplasma pathogenesis. In this context I will use the well-characterised Mycoplasma synoviae haemagglutinin, MSPA, to establish the role of its phase-variable expression in the type and extent of M. synoviae disease. Additionally, the relationship between MSPA phase variation and gene rearrangements in the MSPB-encoding gene will be elucidated. The results will contribute to our understanding of the pathogenesis of bacterial disease and of the evolution of pathogenic mechanisms in bacterial pathogens.Read moreRead less
Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This inform ....Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This information will provide the basis for tailoring treatment to a patients needs. It is anticipated that marketing of the PD GeneChip within Australia and overseas may produce revenue of at least $40 million annually.Read moreRead less